In compliance with section 17(b) of the Securities Act, we are disclosing that Organicell Regenerative Medicine, Inc. (NASDAQ: OCEL) is a client of TraDigital Marketing Group, Inc., and OCEL has an agreement in place to compensate TraDigital Marketing Group, Inc. a monthly cash fee of fifteen thousand dollars for investor relations services, and  publicly disseminating information about Organicell Regenerative Medicine, Inc. via website, email, and SMS, and a one-time stock fee of two million five hundred thousand shares of common stock, restricted under Rule 144, for TraDigital Marketing Group, Inc., investor awareness and digital marketing services. The stock is eligible for sale on 02/22/2023. Although we are not obligated to sell our shares, for the purpose of this disclosure, we suggest that you assume we will sell all of our shares once the restriction is lifted on 2/22/2023. 

Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. TraDigital Marketing Group, Inc., investor awareness and advisory services include multimedia marketing and other awareness services.